Investor
As part of the deal Tabula Rasa will acquire the DoseMeRx platform, which gives clinicians information about how a patient will metabolize and absorb certain medications.
ResMed is expected to close the $225M deal to purchase the smart inhaler company by March 2019.
The health startups use AI to tackle a range of problems including malaria, addiction and diabetes.
The company said that it plans to use the funding from Idinvest Partners to scale its virtual care offering.
The company plans to use its oversubscribed round to expand into new markets and beef up its tech platform.
Keyto's platform measures biomarkers in a user's breath to gauge the state of their metabolism.
The latest funding is expected to help the company grow its omnichannel approach to subscription growth, as well as for advertising and marketing.
Also: Duke freshmen to receive free smartwatches for sleep monitoring program; FallCall Lite emergency fall system supports Siri Shortcuts.
The acquisition will allow Medtronic to integrate Nutrino's predictive glycemic response algorithm into its technology.
The New York-based startup also launched a beta version of its prostate cancer screening program.